What is EVOTEC?
Evotec operates as a premier global platform company dedicated to the discovery and development of highly effective therapeutics. By integrating a proprietary, data-driven multimodality platform with a unique combination of innovative technologies, the company addresses complex challenges in drug development. Evotec's market position is defined by its dual-track strategy: advancing its own pipeline of first-in-class assets while simultaneously providing high-value research services to external partners. This hybrid model allows the firm to mitigate risk while maximizing the potential for breakthrough medical discoveries across various therapeutic areas.
How much funding has EVOTEC raised?
EVOTEC has raised a total of $772.9M across 8 funding rounds:
Stock Offering
$69.4M
Share Placement
$32.5M
Share Placement
$96.1M
Debt
$89.8M
Grant
$23.8M
Private Equity
$292.4M
Grant
$8.5M
Debt
$160.4M
Stock Issuance/Offering (1999): $69.4M, investors not publicly disclosed
Share Placement (2013): $32.5M led by Biotechnology Value Fund
Share Placement (2017): $96.1M supported by Novo A/S
Debt (2017): $89.8M featuring European Investment Bank
Grant (2019): $23.8M backed by Bill & Melinda Gates Foundation
Private Equity (2020): $292.4M with participation from Mubadala and Novo Holdings
Grant (2022): $8.5M led by German Federal Ministry of Education and Research
Debt (2023): $160.4M supported by European Investment Bank
Key Investors in EVOTEC
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, the European Investment Bank is the European Union's nonprofit long-term lending and finance institution.
Bill & Melinda Gates Foundation
A global philanthropic organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives through strategic health investments.
What's next for EVOTEC?
With the recent infusion of $160.4M, Evotec is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its technological infrastructure and the deepening of its therapeutic pipeline. The company is expected to prioritize the integration of advanced AI-driven analytics into its discovery processes, further enhancing the efficiency of its multimodality platform. As the firm moves into its next phase of growth, the focus will likely remain on scaling its research capacity to meet the increasing demand for precision medicine. By maintaining its commitment to collaborative research and internal innovation, Evotec is poised to sustain its leadership in the biotechnology sector, driving long-term value for stakeholders and patients alike.
See full EVOTEC company page
